iPS cell therapy 2.0: Preparing for next‐generation regenerative medicine

• Published in: BioEssays 2024-12, Vol.46 (12), p.e2400072-n/a
• Main Authors: Hui, Kelvin K., Yamanaka, Shinya
• Format: Article
• Language: English
• Subjects: Allografts; Animals; Bioengineering; Cell therapy; Cell- and Tissue-Based Therapy - methods; Chimeric antigen receptors; Clinical trials; Fabrication; Humans; Induced Pluripotent Stem Cells - cytology; iPS cells; Lymphocytes; Lymphocytes T; Pluripotency; Precision medicine; Precision Medicine - methods; Receptors, Chimeric Antigen - immunology; Regenerative medicine; Regenerative Medicine - methods; Stem cells; Tissue engineering; Tissue Engineering - methods; transplantation
• ISSN: 0265-9247; 1521-1878; 1521-1878
• DOI: 10.1002/bies.202400072

This year marks the tenth anniversary of the world's first transplantation of tissue generated from induced pluripotent stem cells (iPSCs). There is now a growing number of clinical trials worldwide examining the efficacy and safety of autologous and allogeneic iPSC‐derived products for treating various pathologic conditions. As we patiently wait for the results from these and future clinical trials, it is imperative to strategize for the next generation of iPSC‐based therapies. This review examines the lessons learned from the development of another advanced cell therapy, chimeric antigen receptor (CAR) T cells, and the possibility of incorporating various new bioengineering technologies in development, from RNA engineering to tissue fabrication, to apply iPSCs not only as a means to achieve personalized medicine but also as designer medical applications. iPSC‐based therapies being tested in clinical trials continue to face many challenges, suggesting much room for improvements by leveraging the latest biomedical and bioengineering breakthroughs. We start with crucial lessons learned from CAR T cell therapy and examine how to incorporate new technologies into iPSC‐based products for next‐generation regenerative medicine.